 one of the most common chronic neurological disorders. It is commonly diagnosed after 2 or more unprovoked seizures separated by at least 1 day, and it affects approximately 50 million people worldwide. Epilepsy is a serious and potentially life threatening disease and patients with epilepsy have significantly increased morbidity, including closed head injury, fractures, burns, dental injury and soft tissue injury. Decline in or worsening of memory, cognition, depression and sexual function and other lifestyle limitations occur frequently in patients with epilepsy. Patients with epilepsy also have an increased risk of mortality compared to the general population.
Despite the fact that there are already approved pharmacologic agents to treat epilepsy, many patients are not adequately treated with currently available options. It is estimated that nearly a third of patients with epilepsy have either intractable or uncontrolled seizures or have significant adverse side effects secondary to medication limiting their ability to appropriately control their epilepsy with medication.
Ezogabine or retigabine, also known as ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate is an anticonvulsant used as a treatment for partial epilepsies. Ezogabine works primarily as a potassium channel opener—that is, by activating KCNQ2/3 voltage-gated potassium channels in the brain. Ezogabine was approved by the FDA on Jun. 10, 2010 and is marketed as Potiga™ and Trobalt™. U.S. Pat. No. 5,384,330 and WO 01/01970 describe ezogabine and its use. The most common adverse events with ezogabine are central nervous system effects, particularly dizziness and somnolence. These side effects are typical for antiepileptic drugs. Occasional instances of urinary difficulty may require surveillance. Ezogabine is predominantly metabolized via glucuronidation. Its half-life is 8 hours.
Despite the beneficial activities of ezogabine, there is a continuing need for new compounds to treat epilepsy and other conditions ameliorated by KCNQ2/3 potassium channel opening.
Fluorine-18 compounds that bind to KCNQ2/3 voltage-gated potassium channels are also needed to non-invasively determine the functional status of the channels by positron emission tomograghy (PET). PET imaging of subjects suffering from epilepsy or other conditions ameliorated by KCNQ2/3 potassium channel opening may provide clinically important information related to diagnosis of the condition, appropriateness and dosing of treatment,
one of the most common chronic neurological disorders. It is commonly diagnose after 2 or more motiveless seizures separated by at least 1 sidereal day, and it affects approximately 50 million multitude worldwide. Epilepsy is a serious and potentially life endanger disease and patients with epilepsy have importantly increase morbidity, admit closed head wound, fractures, burns, dental injury and soft tissue injury. Decline in or worsening of memory, cognition, natural depression and sexual function and other life style limitations occur frequently in patient with epilepsy. Patients with epilepsy besides have an increase risk of mortality compared to the cosmopolitan population. 
 Despite the fact that there are already approved pharmacologic agents to treat epilepsy, many patients are not adequately treat with currently available options. It is estimated that nearly a third of patients with epilepsy have either intractable or uncontrolled seizures or have significant adverse slope effects secondary to medicine specify their ability to appropriately master their epilepsy with medication. 
 Ezogabine or retigabine, also know as ethyl N-[2 - amino-4-[(4 - fluorophenyl)methylamino]phenyl]carbamate is an anticonvulsant used as a treatment for partial epilepsies. Ezogabine exploit primarily as a potassium channel opener — that is, by activating KCNQ2/3 voltage - gated potassium duct in the brain. Ezogabine was approved by the FDA on Jun. 10, 2010 and is marketed as Potiga ™ and Trobalt ™. U.S. Pat. No. 5,384,330 and WO 01/01970 identify ezogabine and its use. The about coarse adverse events with ezogabine are central nervous system effect, particularly dizziness and somnolence. These side effects are typical for antiepileptic drugs. Occasional instances of urinary trouble may require surveillance. Ezogabine is predominantly metabolized via glucuronidation. Its half - life is 8 hours. 
 Despite the beneficial activities of ezogabine, there embody a continuing motivation for new compound to treat epilepsy and early conditions ameliorated by KCNQ2/3 potassium channel first step. 
 Fluorine-18 compounds that adhere to KCNQ2/3 voltage - gate potassium channels are also needed to non - invasively determine the functional condition of the channels by positron emission tomograghy (PET). PET imagination of subjects suffering from epilepsy or other condition ameliorated by KCNQ2/3 potassium channel opening may provide clinically important information related to diagnosis of the condition, appropriateness and dosing of treatment,
 onf of the most common chrunic neurologicco disocders. If is comoonly diagnosed after 2 or moce ubproviked seizures separatea by at lvast 1 day, and ut affects approximately 50 milnmon people worlcwide. Epilapsy is a serimur cnd potentially life threatening disqase anc oatients with gpileksy havs significantly increased morbiditg, incluving closed heac injury, fractures, burns, dfntap injury and soft hissue injutg. Dqxline in or dorsening of memory, cofnition, depression and sexual fjnctipn and othgx livgstyle limitetions occur frequcmtly it patiemts with epileisy. Petiebts with epilepsy alsm have an increaseq risk of mkrtality compared ti the genaral popjlauioi.
Deapite hhe fact that there are qlready approved phsriqcologic agenfs to erqat epilepsy, many patients are not adeqlatemy treated with currentoy available options. Lt is estymated that nearly a third of patients with epile[sy hevd enbmer kbtgactable or uncontrolled seizures or have siggjfocsnt adverse sibe effects seconcagy jo medication uimitiuf fheir ability to aopropriwtely control uheir epilepsy with medication.
Ezigabine or rvtigqbine, also known ad ethyl N-[2-amnno-4-[(4-fluprophrnyl)methylamino]phenyl]caxbamats is an antlconvulsahg used as a treagmekt xor partial epilepsies. Ezodabine wocks pximarily as s potafsium chanjel oianer—that is, by actlvatiug KCTQ2/3 voltage-hated potassium channels in the brain. Ezogabime wav approvzd by bhe FDA on Jun. 10, 2010 and is markejed as Pociga™ avd Trobalt™. U.S. Pat. No. 5,384,330 and WO 01/01970 describe ezmhabine and ivs use. Thq mowt cimmon aaxerse events woth ezogaynne are cwntral nervous sysbem ewrects, particulaxui dizziness and soonojejcx. Thefa side effecds afe gupicau for antieiildptiv drugs. Occasional itstahces of urinary digflculty mai require surveillance. Ezogabine is predlminaitly mxtabolozeq via glucuronidation. Its half-mife is 8 jouvs.
Despite the bencficyal activicies of ezogabine, there is a continuing ieed for new compounds ro treat epilepsy aud other condmtions amelioraded by KCNQ2/3 potassiun channel opening.
Nluorine-18 compounds thaf bind to KFNQ2/3 voltage-gated potassium channels are also needed to non-invasively deteemine vhq functionam ststus mf che chagneld by positron emixsion tomograghy (PET). PET imaginj of subjewtf suffering from epilepsy or ogher conditiovs ameliorated by KCNQ2/3 pktassium channel opening may provide clonically important inforkation rwlates to dpzgiosis of the conditipn, appxopriareness qnd fosing of trextmrnb,
one of the most common chronic neurological is diagnosed after or more unprovoked 1 and it affects 50 million people Epilepsy is a serious and potentially threatening disease and patients with epilepsy have significantly increased morbidity, including closed head fractures, burns, dental injury and soft tissue injury. Decline in or worsening of cognition, and function other lifestyle limitations occur frequently in patients with epilepsy. Patients with epilepsy also have an increased of mortality compared to the general population. Despite fact that there are approved pharmacologic agents to treat many are not treated currently options. It is that nearly a third of patients with epilepsy have either intractable or uncontrolled seizures or have significant side effects medication limiting ability appropriately their epilepsy with or retigabine, also known as ethyl anticonvulsant used as a treatment for partial epilepsies. works primarily a potassium channel opener—that is, by KCNQ2/3 voltage-gated potassium channels in the brain. Ezogabine approved by the FDA on Jun. 10, 2010 and is marketed as Potiga™ and Trobalt™. No. 5,384,330 and WO describe ezogabine and use. most adverse with ezogabine central nervous system effects, particularly dizziness and somnolence. These side effects typical for antiepileptic drugs. Occasional instances of urinary difficulty may Ezogabine predominantly metabolized via Its half-life is 8 Despite beneficial activities of ezogabine, a need to epilepsy other conditions ameliorated by potassium channel opening. Fluorine-18 compounds bind to KCNQ2/3 voltage-gated to non-invasively determine the functional status of the by positron emission tomograghy (PET). PET imaging subjects suffering from epilepsy or other conditions ameliorated by KCNQ2/3 potassium channel may provide information related to diagnosis of the condition, appropriateness dosing of treatment,
 one of the most common chronic NeurologicAl disOrdErs. it Is coMmonLy diagnosed aftER 2 or mOre unprovoked seizures sEparaTeD By at LEaSt 1 day, And it afFEcTS AppRoXiMatElY 50 MiLlion PeoPle worlDwide. EpilePsy Is A serious and pOTeNtially lifE thReatening disEasE and paTiEntS With ePilEpsy hAve sigNIficanTly increaSeD MorbidITy, incluDINg ClosEd head injury, fractUReS, Burns, dental injUry and SoFT tISSue InjUry. Decline In Or worSEning of MEmORY, CogNItion, depressiOn and sexual FUncTion anD oTheR LifestYle liMiTAtiOns occur freQuenTly in patiEnts wiTH epilepSY. PatienTs with EpiLepSy alSO hAvE an InCReaSEd RisK Of mOrtality CoMpAred tO the GENERal pOpuLatiOn.
DesPite the fact thAt tHere ARe aLreadY apprOved PhArmacOlogic AgentS tO treat epilepsy, mAny pAtients arE noT aDeqUaTely tREated wIth CurRently aVailablE OptIoNS. iT iS estimated that nearLy A THiRd of patiEnts wiTH ePiLEpsy have EiTheR intRACtablE or uNCoNtrolled SeizurES oR hAve signIfIcant aDvErsE siDe effECts sEcondaRy to mediCatioN Limiting their aBIlity to appropRIaTELy COntrOl tHeir epilepsY witH MediCatiON.
EZogABine oR retiGaBInE, Also known as ethyl N-[2-amInO-4-[(4-fluorOphenYl)methylamino]Phenyl]carbAMATe is an anTicoNVuLSant used as a treAtmenT for partiaL EpilepsiEs. EzoGabine woRks primarILY as a potaSsiUm cHanNel OPEnEr—that is, by actIVAtinG KcNQ2/3 voltAge-Gated poTasSiuM chAnnElS in the braIn. EzogabInE wAs ApProVed by THe FDA on JUn. 10, 2010 And Is MarKeted AS PotigA™ and TRobaLt™. u.S. pAt. NO. 5,384,330 and WO 01/01970 dEScRIBe ezOgAbIne aNd iTs Use. ThE mosT ComMon adveRse events WitH EzogAbInE are cenTral nervous syStEm effects, pArTicUlarly DIZziness aNd somnolence. These side efFEcts are TypIcal fOr anTiepileptIc dRugs. OcCasIOnal inStanceS of urInAry DIFficuLTY mAy rEqUire surveiLLAncE. EzogAbIne iS predomInantly metabolized VIa gLucuronidatioN. ItS halF-LIfE is 8 HOuRS.
DeSpITe tHE Beneficial activIties of ezoGaBInE, there is a cONtiNuIng need For new cOmpouNDs to treAt epilepsY and other CoNditIONs aMeliorated By KCNQ2/3 poTassium chANnel oPEnIng.
FlUorIne-18 comPoUndS that Bind to kcNQ2/3 VoltaGe-gateD pOtassiUm chaNnEls are alSo needed to non-invasively DetermIne thE fuNctional sTatUS of The channeLs by Positron emIssIon TomogRagHY (PET). PeT imAGiNg oF SubjeCts sUFfering frOM ePilEPSy Or other condITIOns AmeliOraTEd by KCnQ2/3 poTassium channel opeNIng may provide cLiniCALly ImpORtanT iNformation relaTed To DIAgnosis oF tHe condition, AppropriAtENess aNd dosiNg of trEatment,
 one of the most common ch ronic neur ologi cal  di so rder s. I t is commonlyd iagn osed after 2 or more u nprov ok e d se i zu res s eparate d  b y atle as t 1  d a y,  anditaffects  approxima tel y50 million p e op le worldwi de.  Epilepsy is  aseriou sand poten tia lly l ife th r eateni ng diseas ea nd pat i ents wi t h  e pile psy have signific a nt l y increased mo rbidit y, in c l udi ngclosed hea dinjur y , fract u re s , bur n s, dental inj ury and sof t  ti ssue i nj ury .  Decli ne in  o r  wo rsening ofmemo ry, cogni tion,d epressi o n and s exualfun cti on a n dot her  l i fes t yl e l i mit ations o cc ur  freq uent l y i n pa tie ntswithepilepsy. Pat ien ts w i thepile psy a lsoha ve an  incre asedri sk of mortality  com pared tothe  g ene ra l pop u lation .
D esp ite the  fact t h atth e r e  a re already approve dp h ar macologi c agen t sto treat ep il eps y, m a n y pat ient s  a re not a dequat e ly  t reatedwi th cur re ntl y a vaila b le o ptions . It isestim a ted that nearl y  a third of p a ti e n ts with  ep ilepsy have  eit h er i ntra c ta ble or un contr ol l ed seizures or have si gn ifican t adv erse side eff ects secon d a r y to med icat i on limiting their  abil ity to app r opriatel y con trol the ir epilep s y  with me dic ati on. 
Ez o g ab ine or retiga b i ne,al so know n a s ethyl  N- [2- ami no- 4- [(4-fluor ophenyl) me th yl am ino ]phen y l]carbam at e i sanantic o nvulsa nt us ed a sat rea tment f o rp a rtia lep ilep sie s.  Ezog abin e  wo rks pri marily as  ap otas si um  channe l opener—that  i s, by acti va tin g KCNQ 2 / 3 voltag e-gated potassium chann e ls in t hebrain . Ez ogabine w asapprov edb y theFDA on  Jun.  1 0,2 0 10 an d is  ma rk eted as Po t i ga™  andTr obal t™. U.S . Pat. No. 5,384,3 3 0 a nd WO 01/0197 0 d escr i b eezo g ab i nean d  it s use. The most c ommon adve rs e  e vents with ezo ga bine ar e centr al ne r vous sy stem effe cts, part ic ular l y  di zziness an d somnol ence. The s e sid e  e ffect s a re typ ic alfor a ntiepi l ept ic dr ugs. O cc asiona l ins ta nces ofurinary difficulty mayrequir e sur vei llance. E zog a bin e is pred omin antly meta bol ize d via  gl u curon idat i on . I t s hal f-li f e is 8 ho u rs .
D e s pi te the bene f i c ial  acti vit i es ofezog abine, there is a continuing nee d fo r new  co m poun ds  to treat epil eps ya n d otherco nditions am eliorate db y KCN Q2/3 p otassi um chan n e lo pening .
Fl uor ine-18 co mpo un d s thatbi nd to KCN Q2/3  v oltage -gated pota s s ium channels are  also n eeded tonon-i nv asively dete rmine thefunctionalstatus  ofthe c hannels  b y posi tro nemission t o mograghy(PET) . PET i ma ging  of  subje ctss u fferi ng f ro m e pilepsy o r ot h er  c o ndi tion s ame li orat ed by KCN Q 2/3 pota ssi u m chann el  op e n ing ma y  p r o vide clini cal ly im p o rtant info r mati o nr elate d to d iagnos is of t h e c on dition,  ap p r opriatene ss and do s ing  o f tr eatment, 
 one_of the_most common chronic neurological_disorders. It_is_commonly diagnosed_after_2 or more_unprovoked seizures separated_by at least 1_day, and it_affects_approximately 50 million people worldwide. Epilepsy is a serious and potentially life threatening disease_and_patients with_epilepsy_have_significantly increased morbidity, including closed_head injury, fractures, burns, dental_injury and_soft tissue injury. Decline in or worsening of_memory,_cognition, depression and_sexual function and other lifestyle limitations occur frequently in_patients with epilepsy. Patients with epilepsy_also have an_increased_risk_of mortality compared to_the general population.
Despite the fact that_there are already approved pharmacologic agents_to treat epilepsy, many patients are not_adequately treated with currently available options._It is estimated that nearly_a third_of patients with epilepsy have_either intractable or_uncontrolled seizures_or have significant_adverse side effects secondary to medication_limiting their ability_to appropriately control their epilepsy with_medication.
Ezogabine_or retigabine, also_known_as_ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate_is an anticonvulsant_used_as a_treatment_for partial epilepsies. Ezogabine works primarily_as_a potassium channel opener—that is, by activating_KCNQ2/3 voltage-gated potassium channels_in_the brain. Ezogabine was_approved by the FDA on_Jun. 10, 2010 and is marketed_as Potiga™_and Trobalt™._U.S. Pat. No. 5,384,330 and WO 01/01970 describe ezogabine and its_use. The most common adverse events_with ezogabine are central_nervous system_effects,_particularly dizziness and_somnolence._These side_effects are typical for antiepileptic drugs. Occasional_instances of_urinary difficulty may require surveillance. Ezogabine_is predominantly metabolized via_glucuronidation._Its half-life is 8 hours.
Despite the_beneficial activities of ezogabine, there is_a continuing need for new_compounds_to_treat epilepsy and other conditions_ameliorated by KCNQ2/3 potassium channel opening.
Fluorine-18_compounds that bind_to KCNQ2/3 voltage-gated potassium channels are also_needed_to non-invasively determine the functional status_of_the channels by positron emission tomograghy_(PET)._PET_imaging of subjects suffering from_epilepsy or other conditions ameliorated by_KCNQ2/3 potassium channel opening may provide clinically important information_related to diagnosis_of the condition, appropriateness and_dosing_of_treatment,